MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells

Oncogene

Volumn 32, Issue 2, 2013, Pages 190-197

  Shi, Y ^a,b   Frost, P ^a,b   Hoang, B ^a,b   Yang, Y ^a,b   Fukunaga, R ^a,b   Gera, J ^a,b   Lichtenstein, A ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

c myc; IRES activity; MNK kinases; mTOR inhibitors; multiple myeloma; rapamycin

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MNK KINASE; MYC PROTEIN; PHOSPHOTRANSFERASE; RAPAMYCIN; RNA; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

5' UNTRANSLATED REGIONS; ANILINE COMPOUNDS; ANIMALS; BUTADIENES; CELL LINE, TUMOR; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GENES, MYC; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MULTIPLE MYELOMA; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; PURINES; PYRIDINES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIROLIMUS; TOR SERINE-THREONINE KINASES; UP-REGULATION;

MURINAE;

EID: 84872194815     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.43     Document Type: Article

References (32)

1. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Peterson R et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci 2001; 98: 10314-10319. (Pubitemid 32803017)
2. Gera J, Mellinghoff I, Shi Y, Rettig M, Tran C, Hsu JH et al. AKT activity determines sensitivity to mTOR inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279: 2737-2746. (Pubitemid 38114263)
3. Frost P, Moatomed F, Hoang B, Shi Y, Gera J, Yan H et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004; 104: 4181-4187. (Pubitemid 39620172)
4. Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002; 62: 5027-5034. (Pubitemid 34984430)
5. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc IRESdependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK-And ERK-dependent pathway. J Biol Chem 2005; 280: 10964-109973.
6. Frost P, Shi Y, Hoang B, Gera J, Lichtenstein A. Regulation of D-cyclin translation inhibition in myeloma cells treated with mTOR inhibitors: Rationale for combined treatment with ERK inhibitors and rapamycin. Mol Cancer Ther 2009; 8: 83-93.
7. Subkhankulova T, Mitchell SA, Willis AE. IRES-mediated initiation of c-myc protein synthesis following genotoxic stress. Biochem J 2001; 359: 183-192. (Pubitemid 32939220)
8. Stoneley M, Chappell SA, Jopling CL, Dickens M, MacFarlane M, Willis AE. C-myc protein synthesis is initiated from the IRES during apoptosis. Mol Cell Biol 2000; 20: 1162-1169. (Pubitemid 30069236)
9. Parra JL, Buxade M, Proud CG. Features of the catalytic domains and C termini of the MAPK signal-integrating kinases MNK1 and MNK2 determine their differing activities and regulatory properties. J Biol Chem 2005; 280: 37623-37633. (Pubitemid 41642371)
10. Wang X, Yue P, Chan C-B, Ye K, Ueda T, Watanabe-Fukunaga R et al. Inhibition of mTOR induces PI3-kinase-dependent and MNK-mediated eIF-4E phosphorylation. Mol Cell Biol 2007; 27: 7405-7413.
11. Ross G, Dyer JR, Castellucci VF, Sossin WS. MNK is a negative regulator of cap-dependent translation in Aplysia neurons. J Neurochem 2006; 97: 79-91.
12. Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N et al. The MNKs are novel components in the control of TNF alpha biosynthesis andphosphorylate and regulate hnRNP A1. Immunity 2005; 23: 177-189. (Pubitemid 41169287)
13. Scheper GC, Morrice NA, Kleijn M, Proud CG. The mitogen-Activated protein kinase signal-integrating kinase MNK2 is an eIF-4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol 2001; 21: 743-754. (Pubitemid 32104723)
14. Scheper GC, Parra J-L, Wilson ML, van Kollenburg B, Vertegaal ACO, Han ZG et al. The N and C termini of the splice variants of the human MNK2 determine activity and localization. Mol Cell Biol 2003; 23: 5692-5705.
15. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. MNK2 and MNK1 are essential for constitutive and inducible phosphorylation of eIF-4E but not for cell growth or development. Mol Cell Biol 2004; 24: 6539-6549. (Pubitemid 38944335)
16. Parra-Palau JL, Scheper GC, Wilson ML, Proud CG. Features in the N and C termini of the MAPK-integrating kinase MNK1 mediate its nucleocytoplasmic shuttling. J Biol Chem 2003; 278: 44197-44204. (Pubitemid 37377163)
17. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eIF4G recruits MNK1 to phosphorylate eIF-4E. EMBO J 1999; 18: 270-279.
18. Chrestensen CA, Shuman JK, Eschenroeder A, Worthington M, Gram H, Sturgill TW. MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines. J Biol Chem 2007; 282: 4243-4252. (Pubitemid 47100950)
19. Stoneley M, Willis AE. Cellular IRESes: structures, trans-Acting factors and regulation of gene expression. Oncogene 2004; 23: 3200-3207. (Pubitemid 38638831)
20. Paulin FEM, West MJ, Sullivan NF, Whitney RL, Lyne L, Willis AE. Aberrant translational control of the c-myc gene in multiple myeloma. Oncogene 1996; 13: 505-513. (Pubitemid 26283847)
21. Chappell SA, LeQuesne JPC, Paulin FEM, deSchoolmeester ML, Stoneley M, Soutar RL et al. A mutation in the c-myc IRES leads to enhanced internal ribosome entry in multiple myeloma: A novel mechanism of oncogene de-regulation. Oncogene 2000; 19: 4437-4440.
22. Sun S-Y, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of AKT and eIF4E survival pathways by rapamycin-mediated mTOR inhibition. Cancer Res 2005; 65: 7052-7058. (Pubitemid 41161231)
23. Shi Y, Frost PJ, Hoang B, Benavides A, Sharma S, Gera J et al. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc IRES function and the RNA-binding protein hnRNP A1. Cancer Res 2008; 68: 10215-10222.
24. Jo OD, Martin J, Bernath A, Masri J, Lichtenstein A, Gera J. Heterogeneous nuclear ribonucleoprotein A'1 regulates cyclin D and c-myc IRES function through AKT signaling. J Biol Chem 2008; 283: 23274-23287.
25. Zhu Y, Sun Y, Mao O, Jin KL, Greenberg D. Expression of poly(C) binding proteins is differentially regulated by hypoxia and ischemia in cortical neurons. Neuroscience 2002; 110: 191-198. (Pubitemid 34214938)
26. Evans JR, Mitchell SA, Spriggs KA, Ostrowski J, Bomsztyk K, Ostarek D et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc IRES in vitro and in vivo. Oncogene 2003; 22: 8012-8020. (Pubitemid 37175865)
27. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 1-14.
28. Farag SS, Zhang S, Jansak BS, Wang X, Kraut E, Chan K et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 2009; 33: 1475-1480.
29. Ogata A, Chauhan D, Teoh G, Treon S, Urashima M, Schlossman RL et al. IL-6 triggers cell growth via the RAS-dependent mitogen-Activated protein kinase cascade. J Immunol 1997; 159: 2212-2221. (Pubitemid 127681011)
30. Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP. RAS mutations in multiple myeloma. Oncogene 1990; 5: 1569-1663.
31. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116: 4560-4568.
32. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-Activated protein kinases activate the serine/threonine kinses MNK1 and MNK2. EMBO J 1997; 16: 1909-1920. (Pubitemid 27170952)